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Background
Activation of membrane guanylate cyclase type C (GC-C)
on the luminal surface of the intestinal epithelium by GC-
C agonists results in an increase in both intracellular and
extracellular levels of cyclic guanosine monophosphate
(cGMP). Elevation in intracellular cGMP results in the
secretion of chloride and bicarbonate anions into the
intestinal lumen through the activation of the cystic fibro-
sis transmembrane conductance regulator (CFTR) ion
channel. Physiologically, this results in increased intestinal
fluid and accelerated transit. Furthermore, an accompany-
ing increase in the luminal and submucosal concentration
of cGMP is observed as intracellular cGMP is transported
out of epithelial cells. In animal models, decreased activity
of pain-sensing afferent fibers is likely mediated by
increased extracellular cGMP in the submucosa [1].
Compared to the pharmacological effects elicited by the
increase in cGMP, less is known about the distribution
and metabolic fate of this second messenger that is trans-
ported out into the luminal space.
Results and conclusion
We used radiolabeled 14C-cGMP to assess the presence
and metabolism of cGMP following oral administration in
different regions of the gastrointestinal tract in rats, as
well as in plasma and urine. In tracking the levels of 14C-
cGMP and its metabolites we developed a better under-
standing of the fate of orally dosed cGMP in the intestinal
tract, which has implications for the mechanism of action
of cGMP in decreasing gastrointestinal pain. Specifically,
we hypothesize that cGMP may act on intestinal afferent
fibers while travelling along the small intestine whose pro-
jections converge on second order neurons that also
receive input from colonic afferents, thus affecting their
function. In this context, we showed that more than 50%
of the dosed cGMP is available in the small intestine
2 hours after dosing. Little/no 5’GMP or other metabolites
were detected in the luminal contents. In contrast, 40-50%
of cGMP metabolites were found in tissue samples.
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